Compare Davita Inc (DVA) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs ProShares UltraPro QQQ ETF — how do they compare? Davita Inc trades at $181.66 (market cap $11.38B), while ProShares UltraPro QQQ ETF trades at $75.1. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | TQQQ | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $87.22 |
52-Week Low | $103.87 | $37.89 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.
The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.
TQQQ trades at $75.13, up 1.82% with a bullish technical signal supported by moving averages. The ETF leverages Nasdaq-100 exposure, amplified by 3x daily returns. Recent institutional buying includes Bay Colony Advisory's 7,786 share acquisition. Technical indicators show RSI at 74.38 suggesting overbought conditions, while ADX indicates strong trend momentum. Support levels begin at $72 with resistance at $74-$76.
Outlook remains positive given AI-driven tech momentum, but leverage amplifies volatility risks. The ETF's structural costs compound daily, potentially eroding long-term returns despite short-term gains. Investors face significant downside risk during market corrections, as evidenced by recent 14% single-day declines. Current levels warrant caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
